Key facts
- It has raised $1.1M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Austria Wirtschaftsservice, INiTS Universitäres Gründerservice, MCN Pharma-Beteiligungen GmbH.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for ProFem
- ·The full record, as it builds
Funding rounds
No funding rounds for ProFem are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProFem
Operator of a pharmaceutical company intended for the clinical development of drugs for the treatment of women's diseases. The company offers new treatment options for frequently recurring and chronic infections of the lower female genital tract, where infections are often associated with the formation of biofilms, enabling healthcare providers to treat gynaecological diseases with high therapeutic need in women.
- Sector
- Healthcare
- HQ
- Vienna, Austria
- Founded
- 2012
- Employees
- 8
- Website
- profem.at/
- Ownership
- Privately Held (backing)
ProFem doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProFem shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProFem in its N-PORT filings yet. We sweep new filings monthly.